Global Veterinary Vaccines / Animal Vaccines Market Report 2026–2031

In our Mraket Reports Series – we present fairly extensive details on the Global Veterinary Vaccines / Animal Vaccines Market 29026 – 2030. For any further details, queries or suggestions – pls write into us at: info@animalhealthindia.com

A new study by Wissen Research, published on June 4, 2026, projects that the global veterinary vaccines market will experience sustained growth over the next six years, expanding from USD 11 billion in 2025 to USD 15.6 billion by 2031, registering a Compound Annual Growth Rate (CAGR) of 6% during the forecast period 2026–2031. This represents a market expansion of USD 4.6 billion or 41.8% growth over the six-year forecast period, driven by converging factors across companion animal, livestock, and public health sectors.

The market expansion reflects accelerating demand for veterinary preventive healthcare solutions worldwide, with particular momentum in emerging markets where livestock disease concerns and pet ownership are rising simultaneously. Key growth drivers include rising concerns about livestock diseases, zoonotic disease spread, and the growing role of advanced vaccine technologies including mRNA and recombinant platforms.

Market Size and Growth Projections

Core Market

Annualized Growth

The market’s 6% CAGR represents consistent, steady expansion rather than explosive short-term growth. This trajectory reflects the veterinary vaccines market’s characteristics as a mature but expanding sector with predictable demand patterns driven by:

• Biological necessity: Animals require regular vaccination against endemic and emerging diseases

• Regulatory mandates: Government vaccination programs create baseline demand

• Economic value: Vaccination prevents significant economic losses from livestock disease outbreaks

• Consumer awareness: Rising pet ownership drives companion animal vaccine demand

The USD 4.6 billion absolute growth over six years translates to approximately USD 767 million in annual market expansion, indicating substantial opportunities for market participants across the value chain.

Primary Market Growth Drivers

1. Rising Concerns About Livestock Diseases

Livestock disease prevention remains the dominant driver of veterinary vaccine demand globally. The agricultural sector’s increasing reliance on intensive farming systems has elevated disease transmission risks, making vaccination economically critical for:

• Commercial poultry operations: Avian influenza and Newcastle disease pose catastrophic economic threats

• Dairy and beef cattle: Foot-and-mouth disease (FMD) and brucellosis cause massive productivity losses

• Swine production: African swine fever and porcine reproductive and respiratory syndrome (PRRS) devastate herds

• Small ruminants: Peste des petits ruminants (PPR) threatens smallholder livelihoods in developing nations

The economic impact of livestock diseases extends beyond direct animal mortality. Disease outbreaks trigger:

• Trade restrictions on meat and dairy exports

• Production losses from reduced milk yield, weight gain, and egg production

• Treatment costs for affected animals

• Culling requirements for disease containment

These factors establish vaccination as a cost-effective risk management strategy for commercial livestock producers worldwide.

2. Zoonotic Disease Spread Concerns

Growing awareness of zoonotic disease transmission—diseases that jump from animals to humans—has significantly elevated veterinary vaccination’s public health importance. Key zoonotic diseases driving vaccine demand include:

The One Health approach—recognizing the interconnectedness of human, animal, and environmental health—has gained institutional support from WHO, OIE (World Organisation for Animal Health), and FAO, reinforcing vaccination as a critical public health intervention.

3. Advanced Vaccine Technologies: mRNA and Recombinant Platforms

The veterinary vaccine sector is undergoing a technological transformation driven by innovations originally developed for human medicine:

mRNA Vaccine Technology

Messenger RNA (mRNA) vaccine platforms, validated by the successful COVID-19 vaccine rollout, offer significant advantages for veterinary applications:

• Rapid development: mRNA vaccines can be designed and manufactured quickly in response to emerging pathogens

• Safety profile: Non-replicating platforms eliminate risks associated with live-attenuated vaccines

• Scalability: Modular production processes enable rapid volume scaling

• Potency: Strong immune responses with reduced antigen requirements

mRNA veterinary vaccines are advancing for:

• Canine melanoma (companion animal oncology)

• Porcine diseases (PRRS, foot-and-mouth disease)

• Avian pathogens (avian influenza, Newcastle disease)

Recombinant Vaccine Platforms

Recombinant DNA technology enables production of highly specific, safe vaccines by expressing single pathogen antigens:

• Subunit vaccines: Contain only essential pathogen proteins, eliminating risk of disease reversion

• Viral vector vaccines: Use harmless viruses to deliver pathogen genes, inducing strong immunity

• DNA vaccines: Direct injection of genetic material encoding antigens

Recombinant vaccines are particularly valuable for:

• Differentiating infected from vaccinated animals (DIVA) Critical for disease eradication programs

• Safety in pregnant animals: No risk of fetal infection from live vaccines

• Stability: Often more thermostable than traditional vaccines

The integration of these advanced platforms is expected to accelerate market growth by enabling vaccination against previously difficult-to-target pathogens and improving vaccine efficacy and safety profiles.

Secondary Market Growth Drivers

4. Increasing Pet Ownership

The companion animal sector represents the fastest-growing segment of the veterinary vaccines market, driven by demographic and cultural shifts:

Key Pet Ownership Trends

Impact on Vaccine Demand

Increased pet ownership translates directly into vaccine demand through:

• Core vaccination protocols: Dogs and cats require regular vaccinations for rabies, distemper, parvovirus, and respiratory diseases

• Lifestyle-based vaccines: Non-core vaccines for pets with outdoor exposure or boarding needs

• Geriatric pet care: Aging pet populations require booster vaccinations and immunity monitoring

• Preventive healthcare budgets: Pet owners increasingly view vaccination as essential preventive care

The pet humanization trend—where pets are increasingly viewed as family members rather than property—has driven premium spending on veterinary care, including prevention. Owners in developed markets now routinely spend hundreds of dollars annually on pet healthcare, with vaccination representing a baseline expense.

5. Growing Commercial Livestock Populations

Global livestock populations continue expanding to meet rising protein demand from growing and urbanizing populations:

Livestock Population Growth Drivers

Regional Livestock Expansion

• Asia-Pacific: World’s largest livestock region, with China and India driving growth in poultry, swine, and ruminant populations

• Latin America: Brazil and Argentina expanding beef cattle and poultry production for export

• Africa: Growing poultry and small ruminant populations to meet food security needs

• Middle East: Imported protein production through intensive livestock systems

Commercial livestock operations require systematic vaccination programs to protect their investments. Disease outbreaks in intensive farming systems can wipe out entire herds or flocks within days, making vaccination economically essential rather than optional.

6. Government-Led Vaccination Drives

Government vaccination programs represent a critical demand driver, particularly in emerging markets where public health and food security concerns intersect:

Key Government Vaccination Programs

Program Characteristics

Government vaccination programs typically feature:

• Mass vaccination campaigns: Reaching millions of animals annually

• Subsidized or free vaccines: Making vaccination accessible to smallholder farmers

• Mandatory vaccination requirements: For livestock movement and trade

• Surveillance and monitoring: Tracking vaccination coverage and disease prevalence

• International funding: Support from FAO, WHO, World Bank, and regional organizations

India’s National Animal Disease Control Programme (NADCP), launched in 2019, exemplifies large-scale government vaccination efforts. The program targets Foot-and-Mouth Disease (FMD) and Brucellosis, with plans to vaccinate over 500 million cattle, buffalo, sheep, goats, and pigs.

Market Segmentation Analysis

By Animal Type

Livestock Segment Dominance: The livestock segment dominates market share due to:

• Larger animal populations (billions vs. millions of pets)

• Commercial-scale vaccination requirements

• Government vaccination program mandates

• Economic consequences of disease outbreaks

Companion Animal Growth Acceleration: The companion animal segment is growing faster than livestock due to:

• Higher per-animal vaccine spending

• Premium vaccine preferences (recombinant, mRNA)

• Preventive healthcare awareness

• Veterinary clinic accessibility in urban areas

By Vaccine Type

By Disease Type

Regional Market Analysis – North America (United States, Canada)

Europe (EU, UK, Switzerland, Norway)

Asia-Pacific (China, India, Japan, Southeast Asia)